Abstract
Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor inhibitors (ARBs) have been used as standard of care (SoC) for the treatment of diabetes nephropathy (DN) in the United States. Dapagliflozin and saxagliptin have shown to reduce progression of diabetes kidney disease when they are added to the SoC. The present study aimed to determine the cost-effectiveness of dapagliflozin or dapagliflozin plus saxagliptin added to the SoC in diabetes patients with diabetic kidney disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
